Low Bacterial Diet in Patients With Cytopenia

Status Completed

Clinical Trial Summary

The purpose of this prospective, randomized study was to determine the efficacy of low bacterial diet, in comparison to normal hospital diet, with gut colonization by aerobic Gram negative rods and yeasts as primary endpoint. In addition, the occurrence of infections and the total costs of hospital care were documented, in order to identify potential cost savings by the use of either diet.

Clinical Trial Description

Patients with hematological malignancies who receive intensive chemotherapy usually develop a period of cytopenia, during which there is an increased risk of infection. Mucositis can also develop in these patients, enabling micro-organisms, belonging to the endogenous intestinal flora, to translocate from the intestine to the lymphoid tissue and blood. Therefore, when mucositis and cytopenia develop simultaneously, the risk of infection increases further. In this regard bloodstream infection by Gram negative rods and yeasts are an important cause of serious infections causing considerable morbidity.

In order to reduce the risk of infection several preventive measures have been adopted. Fundamentally, all of these measures were designed to prevent either acquisition of Gram negative rods or fungal pathogens from the environment, or the translocation of these potential pathogens across the mucosal barrier of the gut. These measures include protective (or reverse) isolation, antibiotic prophylaxis with antibiotics which selectively eradicate the aerobic Gram negative rods and yeasts from the gut flora, and finally the use of low-bacterial diets.

In this prospective, randomized study on the efficacy of low bacterial diet, in comparison to normal hospital diet, gut colonization by aerobic Gram negative rods and yeasts, the occurrence of infections and the total costs of hospital care were chosen as study endpoints. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00367588
Study type	Interventional
Source	Maastricht University Medical Center
Contact
Status	Completed
Phase	N/A
Completion date	June 2004

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02104440` - Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro	Phase 2
Active, not recruiting	`NCT03682029` - Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies	N/A
Recruiting	`NCT03026751` - Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing	N/A
Recruiting	`NCT04873102` - Danazol for Treatment of Cytopenias in Patients With Cirrhosis	Phase 2
Not yet recruiting	`NCT06285825` - A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia	Early Phase 1
Active, not recruiting	`NCT06276036` - Autoimmune Cytopenias as a Sign of Primary Immunodeficiency.	N/A
Terminated	`NCT03733249` - Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study	Phase 1/Phase 2
Recruiting	`NCT02958462` - Pre-myeloid Cancer and Bone Marrow Failure Clinic Study	N/A
Recruiting	`NCT05236764` - Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion	N/A
Recruiting	`NCT04741945` - Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS	Phase 2
Completed	`NCT01928537` - Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine	Phase 3
Recruiting	`NCT04419649` - A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes	Phase 2
Completed	`NCT04070612` - National Prospective Cohort for Monitoring Children With Severe Autoimmune Cytopenia.
Active, not recruiting	`NCT03301168` - Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant	Phase 1/Phase 2
Terminated	`NCT02065869` - Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant	Phase 1/Phase 2